EOR #4 pharm part 2 Flashcards

1
Q

Dosage forms of Advair Diskus

A

100/50, 250/50, 500/50

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Average daily doses of Advair Diskus

A

One Diskus inhalation twice daily, approximately 12 hrs apart.
For ages 4 yrs and older

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Common indications for Advair Diskus

A

Long-term maintenance treatment of asthma, COPD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MOA of Advair Diskus

A

Fluticasone is a corticosteroid that has extremely potent vasoconstrictive and anti-inflammatory activity
Salmeterol relaxes bronchial smooth muscle by selective action on beta2-receptors with little effect on heart rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Common AEs of Advair Diskus

A
Upper respiratory tract infection
Pharyngitis
HA
Sinusitis
Bronchitis
Rash
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

BBW for Advair Diskus

A

LABAs such as salmeterol may increase the risk of asthma-related death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Clinically sig drug interactions with Advair Diskus

A

Corticosteroids, sympathomimetics, TCAs, and MAOIs may increase toxicity
BBs may decrease the effectiveness of salmeterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Major counseling points of Advair Diskus

A

Avoid contact with eyes
Rinse mouth after use
Not intended for immediate relief of sx
Use on a regular basis for full effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Monitoring parameters of Advair Diskus

A

PFTs
Proper technique
S/sx of asthma/COPD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Dosage forms of methylprednisolone

A

2 mg, 4 mg, 8 mg, 16 mg, 32 mg,

Dosepak: 4 mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Average daily doses of methylprednisolone`

A

4-48 mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Common indications for methylprednisolone

A

Allergic or inflammatory dz

MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

MOA of methylprednisolone

A

Regulate gene expression subsequent to binding specific intracellular receptors and translocation into the nucleus
Modulate carbs, protein, and lipid metabolism and maintenance of fluid and electrolyte homeostasis
CV, immunologic, musculoskeletal, endocrine, and neurologic physiology are influenced
Decreases inflammation by suppression of PMN leukocytes and reversal of increased capillary permeability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Common AEs of methylprednisolone

A
Blurred vision
Upset stomach
Nausea
Vomiting
Fluid and electrolyte disturbances
Agitation
Insomnia
Long-term Cushings
Osteoporosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

BBWs for methylprednisolone

A

Epidural corticosteroid injection may cause neurologic complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Clinically significant drug interactions with methylprednisolone

A

Anticholinesterase
Barbiturates
Estrogens
Ketoconazole

17
Q

Major counseling points of methylprednisolone

A

Take with or without food
Do not d/c on your own
DM pts could see an increase in BG readings

18
Q

Monitoring parameters of methylprednisolone

A

S/sx of inflammation

BG

19
Q

Dosage forms of paroxetine

A

Tabs: 10 mg, 20 mg, 30 mg, 40 mg
Controlled-release tabs: 12.5 mg, 25 mg, 37.5 mg
Oral suspension: 10 mg/5 mL

20
Q

Average daily dosages of paroxetine

A

25 mg to 62.5 mg daily

21
Q

Common indications for paroxetine

A

Depression
Panic d/o
OCD
GAD

22
Q

MOA of paroxetine

A

SSRI, clinically unrelated to tricyclic, tetracyclic, or other antidepressants
Presumably, the inhibition of serotonin reuptake from brain synapse stimulated serotonin activity in the brain

23
Q

Common AEs of paroxetine

A
Nausea
Somnolence
HA
Sexual dysfunction
Dizziness
Asthenia
Wt gain
24
Q

Renal or hepatic dose adjustments for paroxetine

A

CrCl <30 mL/min: adjustment needed

Severe hepatic impairment: adjustment needed

25
Q

BBW for paroxetine

A

Increased suicidal thinking and behavior

26
Q

Clinically sig drug interactions for paroxetine

A

MAOIs

Chronic use with NSAIDs increases risk of GI bleed

27
Q

Major counseling points for paroxetine

A

May cause drowsiness.
Avoid EtOH while taking this med
Therapy may take up to 2 wks to see improvement
Do not abruptly d/c
Pay close attention to any changes in mood, thought, or feelings such as suicidality

28
Q

Monitoring parameters of paroxetine

A

Improvement of S/sx of depression/panic/GAD/OCD
Unusual changes in mood
Suicidality

29
Q

Dosage forms of clonidine

A

Tabs: 0.1, 0.2, 0.3 mg
ER tabs: 0.17 mg
Transdermal XR patch: 0.1 mg/hr, 0.2 mg/hr, 0.3 mg/hr

30
Q

Average daily dosages of clonidine

A

0.1-0.3 mg/day

31
Q

Common indications of clonidine

A

HTN
Opioid detox
Impulse control/ADHD

32
Q

MOA of clonidine

A

Central pre-synaptic alpha 2 receptor antagonist

Reduces the brain’s adrenergic outflow to decrease BP

33
Q

Common AEs of clonidine

A
Drowsiness
Xerostomia
HA
Bradycardia
Rash (transdermal patch)
Dizziness 
Somnolence
34
Q

Clinically sig drug interactions of clonidine

A

TCAs may cause severe hypotension

Avoid CNS depressants

35
Q

Major counseling points of clonidine

A

Do not d/c abruptly d/t rebound HTN
Patches are applied on a weekly basis
Patch site must be rotated on a weekly basis

36
Q

Monitoring parameters of clonidine

A

Decrease in BP

Improvement of S/sx of ADHD/impulse control